Individuals living with heart failure (HF) are predisposed to severe cardio-respiratory disease (CRD) complications following respiratory syncytial virus (RSV) infection. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine reduced the risk of hospitalization for RSV-related respiratory tract disease (RTD),...
K. Skaarup, M. Lassen, M. Yafasov et al.· European Heart Journal· 0 citations
Myocarditis and pericarditis are inflammatory cardiac syndromes that have been monitored as outcomes of special interest in adult vaccination programs. Previous randomized and observational studies of RSVpreF vaccination have not identified an association with these events; however, given their low incidence, pri...
M. Yafasov, M. Pareek, M. Lassen et al.· European Heart Journal· 0 citations
A prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD.
M. Pareek, M. Lassen, M. Yafasov et al.· European Heart Journal· 0 citations
BACKGROUND
Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...
M. Lassen, S. Christensen, M. Yafasov et al.· NEJM Evidence· 1 citation
INTRODUCTION
This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19.
RESEARCH DESIGN AND METHODS
A previously published static decision-tree model was...
A. Yehoshua, M. di Fusco, Abby E. Rudolph et al.· Expert Review of Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.